Start-up ObsEva raises €25.6m, licenses Merck Serono compounds
This article was originally published in Scrip
Executive Summary
Swiss specialty biopharma start-up ObsEva has banked a CHF32m (€25.6m) series A financing, which it plans to use to develop a batch of compounds that it has concurrently licensed from Merck Serono.